Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.77 |
| ▸ | MET | P08581 | 2/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.72 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | NPM1 | P06748 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846990 | 0.87 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL25306773 | 0.86 | EGFR (0.77) | EGFRMETALK | |
| SCHEMBL21847011 | 0.85 | EGFR (1.00) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL25370138 | 0.85 | EGFR (0.83) | EGFRMETALKINSR | |
| SCHEMBL24207846 | 0.84 | EGFR (0.60) | EGFRMETALKINSR | |
| SCHEMBL25308104 | 0.83 | EGFR (0.85) | EGFRMETALKINSR | |
| SCHEMBL25306866 | 0.83 | EGFR (0.69) | EGFRMETALKINSR | |
| SCHEMBL11919111 | 0.82 | ALK (0.81) | EGFRMETALKINSR | |
| SCHEMBL25299463 | 0.82 | ALK (0.72) | EGFRMETALK | |
| SCHEMBL18181631 | 0.82 | ALK (0.79) | EGFRMETALKNPM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024242360-A1 | CANCER THERAPEUTIC AGENT MEDIATED BY ALK | 주식회사 온코빅스 | 2024-11-28 | — | — | WO | claimed |
| EP-3722292-B1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| CN-111386266-B | Pyrimidine derivatives having cancer cell growth inhibiting effect and pharmaceutical compositions containing the same | 昂科比克斯有限公司 | 2023-08-04 | — | — | CN | claimed |
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2022-02-15 | — | — | US | claimed |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2021-05-20 | — | — | US | claimed |
| EP-3722292-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2020-10-14 | — | — | EP | claimed |
| CN-111386266-A | Novel pyrimidine derivative having cancer cell growth inhibitory effect and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2020-07-07 | — | — | CN | claimed |
| WO-2024242360-A1 | CANCER THERAPEUTIC AGENT MEDIATED BY ALK | 주식회사 온코빅스 | 2024-11-28 | — | — | WO | disclosed |
| EP-3722292-B1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-111386266-B | Pyrimidine derivatives having cancer cell growth inhibiting effect and pharmaceutical compositions containing the same | 昂科比克斯有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2021-05-20 | — | — | US | disclosed |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-3722292-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2020-10-14 | — | — | EP | disclosed |
| CN-111386266-A | Novel pyrimidine derivative having cancer cell growth inhibitory effect and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019190259-A1 | NOVEL SULFONAMIDE DERIVATIVE HAVING INHIBITORY EFFECT ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION | 한미약품 주식회사 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | MET, EGFR, TYMS | EGFR 2/4885MET 1/4885ALK 94/4885 |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | MET, EGFR, TYMS | EGFR 2/4885MET 1/4885ALK 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.